Printer Friendly

Senetek PLC Receives Approval to Market INVICORP(TM), Its Erectile Dysfunction (ED) Therapy, in Denmark

NAPA, Calif., July 13 /PRNewswire/ -- Senetek PLC (Nasdaq: SNTKY) announced today that it has received approval from the Danish Medicines Agency (DMA) to market INVICORP(TM) in Denmark. INVICORP(TM) is Senetek's combination therapy, administered via the Company's proprietary state-of-the- art autoinjector, for treating moderate to severe erectile dysfunction.

"This is the first of many regulatory approvals we are anticipating this year," said Anthony J. Cataldo, chairman and chief executive officer of Senetek. "Because of the continuous clinical data being reported about INVICORP, which show significant efficacy and minimal side effects, coupled with extremely low placebo results, we believe that INVICORP's market segment will represent a substantial percentage of the potential total worldwide market for ED therapies."

INVICORP(TM), an autoinjectable formulation ofvasoactive intestinal polypeptide (VIP), in combination with the adrenergic drug phentolamine mesylate (PMS) and sexual stimulation, provides an effective therapy for ED patients that is essentially free of troublesome side effects and cumbersome delivery methods.

Senetek PLC is a science-driven biotechnology company providing solutions to aging-related healthcare problems.

Statements contained in this news release that state the Company's or management's intentions, hopes, beliefs, expectations or predictions of the future are "forward-looking" statements. It is important to note that the Company's actual results could differ materially from those projected in such forward-looking statements. Additional information concerning factors that could cause actual results to differ materially from those in the forward- looking statements is contained from time to time in the Company's SEC filings, including but not limited to the Company's report on Form 10-Q for the quarter ended March 31, 1998. Copies of this document may be obtained by contacting the Company or the SEC.

Visit Senetek's Web site on the Internet --

 -0- 07/13/98

/CONTACT: Constance L. Adolph of Ronald Trahan Associates Inc., 617-332-0101, ext. 16/

/Company News On-Call: or fax, 800-758-5804, ext. 115015/

/Web site:


CO: Senetek PLC ST: California IN: MTC SU: PDT

KR -- NEM017 -- 6983 07/13/98 08:43 EDT
COPYRIGHT 1998 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1998 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 13, 1998
Previous Article:Digi International Indicates Third Quarter 1998 Results Will Exceed Earnings Expectations
Next Article:Thermo BioAnalysis Acquires Data Medical Associates, Inc.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters